PRGO:NYE-Perrigo Company plc (USD)

EQUITY | Drug Manufacturers - Specialty & Generic | New York Stock Exchange

Last Closing

USD 27.91

Change

+0.21 (+0.76)%

Market Cap

USD 12.59B

Volume

0.84M

Analyst Target

USD 57.88
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Perrigo Co PLC develops, manufactures and distributes over-the-counter and generic prescription pharmaceuticals, nutritional products and active pharmaceutical ingredients.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-04-02 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
ZTS Zoetis Inc

-3.89 (-2.38%)

USD 72.21B
TAK Takeda Pharmaceutical Co Ltd A..

+0.21 (+1.40%)

USD 47.88B
HLN Haleon plc

+0.29 (+2.85%)

USD 46.89B
RDY Dr. Reddy’s Laboratories Ltd..

+0.01 (+0.08%)

USD 10.62B
ELAN Elanco Animal Health

-1.05 (-9.75%)

USD 5.51B
AMRX Amneal Pharmaceuticals, Inc. C..

-0.36 (-4.41%)

USD 4.11B
BHC Bausch Health Companies Inc

-0.44 (-7.20%)

USD 2.64B
CPHI China Pharma Holdings Inc

-0.01 (-4.56%)

USD 3.69M
YCBD cbdMD Inc

-0.04 (-14.39%)

USD 1.96M
EBS Emergent Biosolutions Inc

-0.34 (-6.58%)

N/A

ETFs Containing PRGO

FLWR:SW 15.27 % 0.00 %

N/A

N/A
XMET:AU BetaShares Energy Transit.. 4.93 % 0.00 %

-0.27 (-5.10%)

N/A
LIMI Themes Lithium & Battery .. 3.86 % 0.00 %

-1.15 (-5.10%)

USD 0.49M
ION Proshares S&P Global Core.. 3.13 % 0.00 %

-1.06 (-5.10%)

USD 2.69M
GNRX 0.00 % 0.55 %

N/A

N/A
PILL Direxion Daily Pharmaceut.. 0.00 % 0.98 %

-0.69 (-5.10%)

N/A
XPH SPDR® S&P Pharmaceutical.. 0.00 % 0.35 %

-1.51 (-5.10%)

N/A
ISRL:LSE 0.00 % 0.00 %

N/A

N/A
TASE:LSE 0.00 % 0.00 %

N/A

N/A
QDVM:F 0.00 % 0.00 %

N/A

N/A
QDVM:XETRA 0.00 % 0.00 %

N/A

N/A
WSRD:CA Wealthsimple Developed Ma.. 0.00 % 0.00 %

-0.96 (-5.10%)

CAD 0.80B
FLWG:LSE 0.00 % 0.00 %

N/A

N/A
FLWR:LSE 0.00 % 0.00 %

N/A

N/A
BLUM:XETRA 0.00 % 0.00 %

N/A

N/A
HLIT:CA Global X Lithium Producer.. 0.00 % 0.00 %

-0.88 (-5.10%)

CAD 0.01B
BLUM:F 0.00 % 0.00 %

N/A

N/A
SMIG ETF Series Solutions - AA.. 0.00 % 0.00 %

-1.29 (-5.10%)

USD 0.90B

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 8.56% 86% B+ 86% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 8.56% 86% B+ 86% B+
Trailing 12 Months  
Capital Gain -10.05% 36% F 23% F
Dividend Return 2.67% 50% F 48% F
Total Return -7.39% 36% F 22% F
Trailing 5 Years  
Capital Gain -37.08% 46% F 8% B-
Dividend Return 10.98% 40% F 21% F
Total Return -26.10% 46% F 8% B-
Average Annual (5 Year Horizon)  
Capital Gain -12.97% 7% C- 5% F
Dividend Return -10.48% 7% C- 5% F
Total Return 2.49% 83% B 56% F
Risk Return Profile  
Volatility (Standard Deviation) 8.07% 100% F 83% B
Risk Adjusted Return -129.88% 7% C- N/A F
Market Capitalization 12.59B N/A N/A N/A N/A

Key Financial Ratios

  Ratio vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A
Price/Book Ratio N/A N/A N/A
Price / Cash Flow Ratio N/A N/A N/A
Price/Free Cash Flow Ratio N/A N/A N/A
Management Effectiveness  
Return on Equity N/A N/A N/A
Return on Invested Capital N/A N/A N/A
Return on Assets N/A N/A N/A
Debt to Equity Ratio N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector